What is BIVI's earnings growth forecast for 2026-2026?
(NASDAQ: BIVI) Biovie's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Biovie's earnings in 2025 is -$19,363,238.
In 2026, BIVI is forecast to generate -$28,029,194 in earnings, with the lowest earnings forecast at -$28,029,194 and the highest earnings forecast at -$28,029,194.
What is BIVI's revenue growth forecast for 2031-2031?
(NASDAQ: BIVI) Biovie's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Biovie's revenue in 2025 is $0.
In 2031, BIVI is forecast to generate $235,370,978 in revenue, with the lowest revenue forecast at $235,370,978 and the highest revenue forecast at $235,370,978.
What is BIVI's forecast return on assets (ROA) for 2026-2028?
(NASDAQ: BIVI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 44.42%.
What is BIVI's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: BIVI) Biovie's current Earnings Per Share (EPS) is -$16.10. In 2026, BIVI's EPS is forecast to hit -$15.10 (min: -$15.10, max: -$15.10).
What is BIVI's forecast return on equity (ROE) for 2026-2028?
(NASDAQ: BIVI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.